ACAM FLU A
Alternative Names: ACAM-Flu-A; ACAM-FLU-A; Influenza A vaccine (ACAM Flu-A) - Sanofi; Recombinant M2e influenza-A vaccine (ACAM FLU-A) - SanofiLatest Information Update: 31 Mar 2022
At a glance
- Originator Acambis; VIB
- Developer Sanofi
- Class Influenza A vaccines; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus infections
Most Recent Events
- 09 Dec 2019 Sanofi Pasteur receives Biomedical Advance Research and Development Authority (BARDA) grant from US Department of Health and Human Services for seasonal influenza virus vaccine quadrivalent for development in Influenza virus infections
- 22 Oct 2013 No development reported - Preclinical for Influenza A virus infections (prevention) in USA (Parenteral)
- 01 Oct 2009 Preclinical trials in Influenza A virus infections (prevention; in volunteers) in USA (Parenteral)